Relapse remains a major cause of failure after allogeneic hematopoietic cell trnaplantation (allo-HCT).
Prophylactic donor lymphocyte infusion (pDLI) could be used to reduce relapse.
However, its widespread application has been restricted mostly due to concerns regarding the development of Graft versus Host Disease (GvHD).
We report on consecutive patients who received a novel method of pDLI based on repetitive administration of a fixed low CD3+ cell dose.


Poster author: Dr Liga 
Participants:  D. Tsokanas , E. Sagiadinou , A. Gkikas , E. Triantafyllou , K. Valera , A. Christopoulou , V. Zacharioudaki , A. Spyridonidis